Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects.

Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, Kim HL, Kim TH, Yoo K, Kim HY.

PLoS One. 2019 Mar 14;14(3):e0213692. doi: 10.1371/journal.pone.0213692. eCollection 2019.

2.

Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.

Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC, Sun CH.

World J Gastroenterol. 2014 Dec 21;20(47):17932-40. doi: 10.3748/wjg.v20.i47.17932.

3.

Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.

Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP.

Clin Gastroenterol Hepatol. 2013 Jul;11(7):868-75.e1-3. doi: 10.1016/j.cgh.2013.02.015. Epub 2013 Feb 27.

PMID:
23454028
4.

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxì A, Fargion S.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.

PMID:
28554682
5.
6.

Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.

Sookoian S, Pirola CJ.

Aliment Pharmacol Ther. 2018 Jan;47(1):16-25. doi: 10.1111/apt.14401. Epub 2017 Oct 30. Review.

PMID:
29083036
7.

Comparison of the gut microbial community between obese and lean peoples using 16S gene sequencing in a Japanese population.

Andoh A, Nishida A, Takahashi K, Inatomi O, Imaeda H, Bamba S, Kito K, Sugimoto M, Kobayashi T.

J Clin Biochem Nutr. 2016 Jul;59(1):65-70. doi: 10.3164/jcbn.15-152. Epub 2016 Apr 29.

8.

Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease.

Pirgon O, Cekmez F, Bilgin H, Eren E, Dundar B.

Obes Res Clin Pract. 2013 Jul-Aug;7(4):e275-83. doi: 10.1016/j.orcp.2012.01.004.

PMID:
24306155
9.

Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.

Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S.

Hepatol Commun. 2017 Nov 30;2(1):48-57. doi: 10.1002/hep4.1124. eCollection 2018 Jan.

10.

An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity.

Nistal E, Sáenz de Miera LE, Ballesteros Pomar M, Sánchez-Campos S, García-Mediavilla MV, Álvarez-Cuenllas B, Linares P, Olcoz JL, Arias-Loste MT, García-Lobo JM, Crespo J, González-Gallego J, Jorquera Plaza F.

Rev Esp Enferm Dig. 2019 Apr;111(4):275-282. doi: 10.17235/reed.2019.6068/2018.

11.

Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.

Miura K, Ohnishi H.

World J Gastroenterol. 2014 Jun 21;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381. Review.

12.

Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease.

Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, Beyersdorf N, Dandekar T, Rosenstiel P, Geier A.

United European Gastroenterol J. 2018 Dec;6(10):1496-1507. doi: 10.1177/2050640618804444. Epub 2018 Sep 30.

13.

Effect of barley supplementation on the fecal microbiota, caecal biochemistry, and key biomarkers of obesity and inflammation in obese db/db mice.

Garcia-Mazcorro JF, Mills DA, Murphy K, Noratto G.

Eur J Nutr. 2018 Oct;57(7):2513-2528. doi: 10.1007/s00394-017-1523-y. Epub 2017 Aug 16.

PMID:
28815303
14.

Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver.

Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, Huber-Schönauer U, Niederseer D, Stickel F, Auer S, Haschke-Becher E, Patsch W, Datz C, Aigner E.

Am J Gastroenterol. 2017 Jan;112(1):102-110. doi: 10.1038/ajg.2016.318. Epub 2016 Aug 16.

PMID:
27527746
15.

NASH in Lean Individuals.

Younes R, Bugianesi E.

Semin Liver Dis. 2019 Feb;39(1):86-95. doi: 10.1055/s-0038-1677517. Epub 2019 Jan 17.

PMID:
30654392
16.
18.

Assessment of Lean Patients with Non-alcoholic Fatty Liver Disease in a Middle Income Country; Prevalence and Its Association with Metabolic Disorders: A Cross-sectional Study.

Naderian M, Kolahdoozan S, Sharifi AS, Garmaroudi G, Yaseri M, Poustchi H, Sohrabpour AA.

Arch Iran Med. 2017 Apr;20(4):211-217. doi: 0172004/AIM.005.

19.

Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.

Akyuz U, Yesil A, Yilmaz Y.

Scand J Gastroenterol. 2015 Mar;50(3):341-6. doi: 10.3109/00365521.2014.983160. Epub 2014 Dec 26.

PMID:
25540973
20.

Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.

Shao C, Ye J, Li F, Feng S, Wang W, Zhong B.

Dig Liver Dis. 2019 Mar 27. pii: S1590-8658(19)30105-7. doi: 10.1016/j.dld.2019.02.019. [Epub ahead of print]

PMID:
30928418

Supplemental Content

Support Center